



Zentrum für Klinische Studien · Frönsbergstraße 23 · 72070 Tübingen

Medizinische Fakultät

ZKS Tübingen
Zentrum für Klinische Studien

Prof. Dr. Wolfgang Bethge
Leitung / Head of the center for clinical trials

Telefon +49 7071 29-85635
Telefax +49 7071 29-25080
wolfgang.bethge@med.uni-tuebingen.de
www.zks-tuebingen.de



Tübingen, 07.09.2021

Prematurely ended - statement

EudraCT number: 2015-005740-34

Full title of the study: Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basal-bolus insulin treatment (BBIT) regimen to a basal supported oral therapy (BOT) in patients with Type 2 Diabetes – a randomized double-blinded study

Study Contact: Prof. Dr. med. Norbert Stefan, Internal Medicine IV, Otfried-Müller-Str. 10, 72076 Tübingen

Sponsor: University Hospital Tuebingen, Medical Director: Prof. Dr. med. M. Bamberg, Director of Administration: G. Sonntag, Geissweg 3, 72076 Tuebingen

Contact email address: norbert.stefan@med.uni-tuebingen.de

Product:

- Dapagliflozin 10 mg (Manufacturer: AstraZeneca)
- Saxagliptin 5 mg (Manufacturer: AstraZeneca)

Date of the early termination of the trial: 03.02.2020

Statement on discontinuation of the study: The study was prematurely terminated on March 3rd 2020 because of low recruitment and high pre-screening failure rate.